27 July 2017 - - San Diego, California-based non-prescription medicine and consumer care products company Innovus Pharmaceuticals, Inc. (OTCQB Venture Market: INNV) has signed an amendment to the exclusive license and distribution agreement with Monaco-based Densmore Pharmaceutical International, a company based in Monaco, for the commercialization of Zestra in Singapore and Vietnam, the company said.
Zestra is currently exclusively partnered with Orimed Pharma, the OTC subsidiary of Jamp Pharma in Canada, DanaLife ApS in select European markets, Sothema Laboratories for the Middle East and North Africa, Elis Pharmaceuticals in Turkey and certain select markets, Luminarie for Australia, New Zealand and the Philippines, BioTask in Malaysia and J and H Co. LTD in South Korea, and non-exclusively to PT Resources in Hong Kong and certain select Asian markets.
Zestra is currently approved to be commercialized in 34 countries of the world, namely, in Canada, the 28 countries of the European Union, Australia, India, Hong Kong, the United Arab Emirates ("UAE"), South Korea, and Morocco.
Innovus currently generates revenues for Zestra in Canada, Morocco, certain European countries, South Korea, and Hong Kong, in addition to the United States as its biggest market.
The company is engaged in the commercialisation, licensing, and development of non-prescription medicine and consumer care products to improve men's and women's health and vitality, and respiratory diseases.
Densmore's research and development center has about 70 years of expertise in vitamin therapy and micro-nutrition formulas. Since the early 2000's, Densmore has acquired new skills in drugs, medical devices, and cosmetics. In addition to its presence in France, Densmore is exported to many countries in Europe and North Africa.